Unlabeled uses of botulinum toxins: a review, part 2.
OBJECTIVE
Efficacy and safety data regarding the unlabeled uses of botulinum toxins are reviewed, and the pharmacology, adverse effects, and characteristics of commercially available botulinum toxins are discussed.


CONCLUSIONS
More than 300 articles have been published on the use of botulinum toxins, particularly botulinum toxin type A, to treat conditions characterized by excessive smooth or skeletal muscle spasticity. Botulinum toxins are synthesized by Clostridium botulinum and cause temporary local paralysis of the injected muscle by inhibiting acetylcholine release at the neuromuscular junction. While botulinum toxins have Food and Drug Administration-approved labeling to treat a limited number of spasticity disorders, including cervical dystonia and blepharospasm, the toxins have more than 50 reported therapeutic uses. Among these uses, the most rigorously studied indications include achalasia, essential tremors, palmar hyperhidrosis, chronic anal fissures, headache prophylaxis, and limb spasticity. The main adverse effects of the toxins are pain and erythema at the injection site, although unintended paralysis of muscles adjacent to the site of toxin injection may also occur.


CONCLUSIONS
Clinical studies support the use of botulinum toxins for certain conditions, although more studies are needed to establish the role of the drug relative to conventional therapies and to determine patient predictors of response. Although botulinum toxins are generally well tolerated, a patient-specific risk-benefit assessment should precede any decision to use them for unlabeled indications.
Cheng
Christine M
CM
University of California at San Francisco, San Francisco, CA 94143, USA. chengc@pharmacy.ucsf.edu
Chen
Jennifer S
JS
Patel
Rosalie P
RP
D019274:Botulinum Toxins, Type A / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004348:Drug Labeling; D017723:Drug Utilization Review; D006801:Humans; D009465:Neuromuscular Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D014481:United States
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A